{"entity":{"id":"nct07718737","kind":"trial","name":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can","aka":[],"tldr":"A phase 2/3 trial of AMT-116 and ramucirumab in lung cancer, run by Multitude Therapeutics Inc., not yet recruiting.","summary":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy is a phase 2/3, randomised interventional study registered as NCT07718737 by Multitude Therapeutics Inc., with a registry enrolment figure of 512 participants, started 2026-08-28 and due to reach its primary completion in 2028-03-30. Interventions recorded: AMT-116; Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab). Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: Number of Participants with Adverse Events as Assessed by CTCAE v6.0. Lung eligibility wording from the registry: \"Diagnosed with non-squamous non-small cell lung cancer (NSCLC) confirmed by pathological or cytological tests\". Sites: Australia, United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07718737","url":"https://clinicaltrials.gov/study/NCT07718737"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":[],"drugs":["amt-116","ramucirumab"],"companies":["multitude-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07718737","phase":"2/3","setting":"Open-Label, Global, Multicenter, Randomized, Phase 2/3 Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy","sponsor":"Multitude Therapeutics Inc.","enrolled":512,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07718737/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"amt-116","kind":"drug","name":"AMT-116","route":"/drugs/amt-116/"},{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/"}],"company":[{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","route":"/companies/multitude-therapeutics/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}